Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
113 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Pipeline Review, H2 2017 Summary Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene. Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation, normal development of the embryonic central nervous system, especially for normal neural crest cell migration, normal axon guidance, mammary gland differentiation, induction of milk proteins and lactation. It acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1, 4, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Gastrointestinal which include indications Gastric Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Colorectal Cancer, Esophageal Cancer, Solid Tumor, Breast Cancer, Glioblastoma Multiforme (GBM), Bile Duct Cancer (Cholangiocarcinoma), Low-Grade Glioma, Lung Adenocarcinoma, Metastatic Brain Tumor, Pancreatic Cancer, Recurrent Glioblastoma Multiforme (GBM), Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Biliary Tumor, Brain Cancer, Cervical Cancer, Chordoma, Chronic Heart Failure, Crohn's Disease (Regional Enteritis), Endometrial Cancer, Ependymoma, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Lung Cancer, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Necrotizing Enterocolitis, Neuroblastoma, Oligodendroglioma, Ovarian Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Rhabdomyosarcoma, Skin Cancer, Systolic Heart Failure, Ulcerative Colitis, Urinary Tract Cancer and Uterine Cancer. Furthermore, this report also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - The report reviews Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Overview 8 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Development 9 Products under Development by Stage of Development 9 Products under Development by Therapy Area 10 Products under Development by Indication 11 Products under Development by Companies 15 Products under Development by Universities/Institutes 22 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Therapeutics Assessment 24 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30 Aslan Pharmaceuticals Pte Ltd 30 Boehringer Ingelheim GmbH 30 GamaMabs Pharma SA 32 Hanmi Pharmaceuticals Co Ltd 32 Jiangsu Kanion Pharmaceutical Co Ltd 33 Minerva Neurosciences Inc 33 Pfizer Inc 34 Puma Biotechnology Inc 35 Shanghai Fosun Pharmaceutical (Group) Co Ltd 36 XuanZhu Pharma Co Ltd 36 Zensun (Shanghai) Sci & Tech Co Ltd 37 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Drug Profiles 38 afatinib dimaleate - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 dacomitinib - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 FCN-411 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 MIN-301 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Monoclonal Antibodies to Antagonize HER4 for Oncology - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 neratinib - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Neucardin - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 NRG-4 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 NT-113 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 PB-357 - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 pirotinib - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 poziotinib - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 sirotinib - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 SKLB-1206 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 varlitinib - Drug Profile 94 Product Description 94 Mechanism Of Action 94 R&D Progress 94 yinlitinib - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Z-650 - Drug Profile 99 Product Description 99 Mechanism Of Action 99 R&D Progress 99 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Dormant Products 100 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Discontinued Products 102 Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Product Development Milestones 103 Featured News & Press Releases 103 Jul 21, 2017: NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting 103 Jul 20, 2017: NERLYNX tablets for HER2+ Breast Cancer in the Extended Adjuvant Setting 103 Jul 19, 2017: Onco360 Chosen For NERLYNX Limited Distribution Pharmacy Network 104 Jul 17, 2017: U.S. Food and Drug Administration Approves Puma's NERLYNX (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer 104 Jul 10, 2017: Lung Cancer: VeriStrat Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy 105 Jul 06, 2017: Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial 105 Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 106 Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 106 Jun 05, 2017: Research suggests possible new treatment for EGFR-positive lung cancer 107 Jun 03, 2017: Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting 108 Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumors at ASCO 109 Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 110 May 30, 2017: NICE Terminates Technology Appraisal for Afatinib in Advanced Squamous NSCLC After Platinum-based Chemotherapy 110 May 22, 2017: Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting 111 May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 111 Appendix 112 Methodology 112 Coverage 112 Secondary Research 112 Primary Research 112 Expert Panel Validation 112 Contact Us 112 Disclaimer 113
List of Tables
Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14 Number of Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 21 Number of Products under Investigation by Universities/Institutes, H2 2017 22 Products under Investigation by Universities/Institutes, H2 2017 23 Number of Products by Stage and Mechanism of Actions, H2 2017 25 Number of Products by Stage and Route of Administration, H2 2017 27 Number of Products by Stage and Molecule Type, H2 2017 29 Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017 30 Pipeline by Boehringer Ingelheim GmbH, H2 2017 31 Pipeline by GamaMabs Pharma SA, H2 2017 32 Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 32 Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 33 Pipeline by Minerva Neurosciences Inc, H2 2017 33 Pipeline by Pfizer Inc, H2 2017 34 Pipeline by Puma Biotechnology Inc, H2 2017 35 Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2017 36 Pipeline by XuanZhu Pharma Co Ltd, H2 2017 36 Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017 37 Dormant Products, H2 2017 100 Dormant Products, H2 2017 (Contd..1), H2 2017 101 Discontinued Products, H2 2017 102
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
